Venetoclax 100mg
| Product Overview | |
| Generic Name | Venetoclax 100mg |
| Brand Name(s) | VENCLEXTA®. |
| Product Type | Originator Brand |
| Form | 120, Film-coated oral tablets |
| Strength | 100mg |
| Therapeutic Class | BCL-2 inhibitor; antineoplastic agent. |
| ATC Code | L01XX52 |
| Manufacturing & Regulatory | |
| Manufacturer | Genentech, AbbVie |
| Country | USA, Canada |
| GMP Compliance | FDA/EMA/WHO-GMP |
| COFEPRIS | 010.000.6226.00 |
| Free Sale Certificate | may obtain export certificate from regulatory authority |
| Logistics & Export | |
| MOQ | 5 units |
| Shelf Life | 24 Months |
| Storage | Store at 20–25 °C |
| Incoterms | EXW, HSN 30049099 |
| Lead Time | 7 - 10 Business Days |
| Documentation | |
| Certificate of Analysis (COA) | Manufacturer provides COA |
| CTD Summary | Not publicly available as parallel traded molecule |
Description
Venetoclax is an oral BCL-2 inhibitor used in adults with chronic lymphocytic leukemia/small lymphocytic lymphoma and, in combination with azacitidine, decitabine, or low-dose cytarabine, in certain adults with newly diagnosed acute myeloid leukemia who are older or not candidates for intensive induction chemotherapy.
